Members of the National Advisory Committee on Immunization (NACI), alongside federal government officials, are expected to provide a technical briefing on NACI’s guidance for the Johnson & Johnson COVID-19 vaccine after quality concerns over Canada’s batch the vaccine prompted the nation’s health agency to withhold the shot’s rollout just days before deployment to the nation’s hardest-hit area.
On Friday, Health Canada announced it was holding back the Johnson & Johnson vaccine, a one-shot dose that experts and health officials touted as crucial in stemming the spread of the virus amid a devastating third wave of the pandemic, after it was revealed that parts of the batch were made in the same Baltimore plant where millions of other doses meant for the U.S. market had spoiled.
Canadians wait eagerly for the 300,000 doses expected to roll out on Monday to hotspots across the country, with leaders of some hotspots expressing disappointment over the vaccines’ delay as cases in some provinces continue to hit record highs.
Health Canada in its statement did not give a timeline on when the review of the vaccine batch would be completed.
For more info, please go to https://globalnews.ca/news/7827753/covid-canada-jj-vaccine-delayed-explained/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB